Mepsevii (Vestronidase Alfa)

Vestronidase alfa is a recombinant human beta‑glucuronidase that, after intravenous infusion, is taken up by cells via mannose‑6‑phosphate receptors and delivered to lysosomes. There it hydrolyzes accumulated glycosaminoglycans, decreasing storage material and mitigating cellular dysfunction associated with MPS VII.

The dosing regimen for Mepsevii is individualized by the prescribing physician based on factors such as patient weight, disease severity, and clinical response. The healthcare professional calculates the appropriate infusion volume and frequency according to the product’s prescribing information.

Safety data for vestronidase alfa in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Consultation with a specialist is recommended before initiating therapy in these populations.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Mepsevii. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Mepsevii is the only approved enzyme replacement therapy that directly addresses the underlying enzyme deficiency in MPS VII. Alternative management options are primarily supportive care, such as physiotherapy, surgical interventions, and symptomatic treatments, which do not replace the missing enzyme.

Mepsevii must be stored refrigerated at 2‑8 °C. It should be protected from light, kept in its original packaging, and must not be frozen or shaken. Proper cold‑chain handling is essential to maintain product stability and efficacy.

Mepsevii is given as an intravenous infusion. The infusion is performed in a clinical setting under medical supervision, with monitoring for infusion‑related reactions. The specific infusion rate and duration are determined by the prescribing physician according to the product label.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, severe infusion reactions (e.g., hypotension, bronchospasm), hepatic enzyme elevations, thrombocytopenia, and pulmonary complications. Patients should be closely monitored during and after infusion for any signs of these events.

Mepsevii is contraindicated in individuals with known hypersensitivity to vestronidase alfa or any component of the formulation. Caution is also advised for patients with severe hepatic impairment, active infections, or those receiving live vaccines, as these conditions may increase the risk of adverse outcomes.